Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Last revisionBoth sides next revision
home:diseases:ibs [03.13.2019] – [Further researxh] sallieqhome:diseases:ibs [03.15.2019] – [Further research] sallieq
Line 53: Line 53:
  
 In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.   (({{pubmed>long:25947920}})) In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.   (({{pubmed>long:25947920}}))
 +
 +Mast cell activation syndromes   (({{pubmed>long:    28780942}}))  
 +
 +Gastrointestinal (GI) symptoms are commonly reported in patients with mast cell disease.  (({{pubmed>long:    30007461}}))  
 +
 + Mast cells are located in close proximity to the vasculature, and vasoactive mediators released upon their activation can promote endothelial activation leading to blood brain barrier (BBB) dysfunction.  (({{pubmed>long:    30837844}}))  
 +
 +Mast cell activation plays an important role in stress-mediated disease pathogenesis.   (({{pubmed>long:30837843}}))  
 +
  
  
home/diseases/ibs.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.